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Abstract
Introduction: The use of recombinant factor VII (rFVIIa) as a last resort for the management of coagulopathy when
there is severe metabolic acidosis during large bleedings in trauma might be deemed inappropriate. The objective
of this study was to identify critical degrees of acidosis and associated factors at which rFVIIa might be considered
of no utility.
Methods: All massively transfused (≥ 8 units of red blood cells within 12 hours) trauma patients from Jan 2000 to
Nov 2006. Demographic, baseline physiologic and rFVIIa dosage data were collected. Rate of red blood cell
transfusion in the first 6 hours of hospitalization (RBC/hr) was calculated and used as a surrogate for bleeding. Last
resort use of rFVIIa was defined by a pH≤ 7.02 based on ROC analysis for survival. In-hospital mortality was
analyzed in last resort and non-last resort groups. Univariate analysis was performed to assess for differences
between groups and identify factors associates with no utility of rFVIIa.
Results: 71 patients who received rFVIIa were analyzed. The pH> 7.02 had 100% sensitivity for the identification of
potential survivors. All 11 coagulopathic, severely acidotic (pH ≤ 7.02) patients with high rates of bleeding (4RBC/hr)
died despite administration of rFVIIa. The financial cost of administering rFVIIa as a last resort to these 11 severely
acidotic and coagulophatic cases was $75,162 (CA).
Conclusions: Our study found no utility of rFVIIa in treating severely acidotic, coagulopathic trauma patients with
high rates of bleeding; and thus restrictions should be set on its usage in these circumstances.
Introduction
Recombinant Factor VIIa (rFVIIa; Novoseven®, NiaStase®)
is a hemostatic agent licensed for the management of
hemorrhagic events and averting bleeding during invasive
interventions in hemophilia A and B patients with FVIII
and FIX inhibitors; acquired hemophilia; congenital defi-
ciency of factor VII; and for the treatment of Glanzmann’s
thrombasthenia [1-3]. It has also been used off-label and
studied in the treatment of coagulopathy in trauma
patients [4-7].
The use of rFVIIa for non-approved indications has
been formally evaluated in clinical trials (including two
randomized controlled trials in trauma) [8-10], and
shown to be of no survival benefit [11]; and with clear
evidence of harm, particularly in the elderly [12].
Despite the lack of supporting evidence, transfusion
guidelines in either military or civilian settings currently
suggest the use of rFVIIa as a last resort for the man-
agement of refractory coagulopathy in trauma [13-16].
However, when the drug is used in these settings of
massive hemorrhage, its efficacy as a pro-hemostatic
agent may vary under different physiologic conditions,
particularly in acidosis [17,18]. In metabolic acidosis,
when pH levels are under 7.2, the activity of rFVIIa is
significantly stunted. In fact, an investigation conducted
by Meng et al. indicated that the activity of rFVIIa
decreased by over 90% at a pH level of 7.0 [17]. Further-
more, high expenditures are associated with off-label use
of rFVIIa [19]. Therefore, the use of rFVIIa as a last
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resort when there is severe metabolic acidosis during
significant hemorrhage in trauma might be considered
inappropriate.
We reviewed a cohort of massively transfused trauma
patients to whom rFVIIa was administered to evaluate its
utility as a last resort for the management of traumatic
coagulopathy. The objective of this study was to identify
critical degrees of acidosis and associated factors at which
the use of rFVIIa might be considered of no utility.
Methods
This study was conducted at Tory Regional Trauma
Centre of Sunnybrook Health Sciences Centre (SHSC), a
large Canadian Level I adult trauma facility. The study
protocol was reviewed and approved by the Hospital
Research Ethics Board.
Study cohort
Patient information was obtained from the Blood Bank
information system (HCLL, Mediware, N.Y.) at SHSC
and the computerized Trauma Registry. The cohort was
comprised of patients admitted from January 1, 2000 to
November 30, 2006, with the following inclusion criteria:
(1) having been massively transfused, defined as having
received 8 or more units of red blood cells (RBCs) within
the first 12 hours (h) of admission (analogous to estab-
lished criterion in recent randomized control trials on
rFVIIa in trauma) [8,9]; (2) having received rFVIIa; (3)
having recorded pH values; (4) and having recorded
times during which dosages of rFVIIa were administered
(from admission to administration).
Last resort use of rFVIIa was defined based on Receiver
Operating Characteristics (ROC) curve analysis for survi-
val. The ROC curve was determined to define a specific
pH cutoff at which the test could appropriately discrimi-
nate the two groups based on the highest sensitivity for
identifying potential survivors. The group with low survi-
val based on the pH cutoff was defined as the group
receiving last resort use of rFVIIa.
Data collection
Demographic data were obtained from the Trauma Reg-
istry and included the following: age, gender, type of
injury, Abbreviated Injury Scale (AIS) score, Injury
Severity Score (ISS), and note of discharge or in-hospital
mortality. Electronic patient records and manual chart
abstraction were used to gather data on in-hospital mor-
tality and admission laboratory values including: platelet
counts, hemoglobin level, arterial pH, International Nor-
malized Ratio (INR), and plasma fibrinogen levels. The
Blood Bank Information System (HCLL, Mediware,
N.Y.) was used to determine patients who received
rFVIIa for coagulopathy treatment within the first 24h
of admission. The same database was utilized to obtain
the time that RBC units were provided, and this infor-
mation was verified by the hospital chart. The rate of
transfusion for the first 6h of hospitalization was deter-
mined for all patients in the cohort. In our previous
experience, this variable, used as a surrogate marker of
the severity of bleeding, has shown to strongly predict
24h in-hospital death [20,21]. The rate of transfusion is
also indicative of severity of injury and the urgency of
treatment.
The price quote of the supplies of rFVIIa was obtained
from the manufacturer and a recently published cost-
effectiveness analysis [19,22]. We conducted cost analysis
pertaining to the drug’s administration as a last resort. We
reviewed the monetary prices of rFVIIa dosages in the
acidotic patients who died despite receiving the drug.
Outcome measures
The main outcome measure was in-hospital mortality.
Secondary outcomes were patient’s physiological covari-
ates (ISS, AIS for head injury, gender, age, fibrinogen,
rate of RBC transfusion within 6h of hospitalization and
INR). The impact of rFVIIa administration was assessed
by comparing outcomes between last resort and non-last
resort cases. Also, sensitivity, specificity, negative predic-
tive value (NPV) and positive predictive value (PPV) were
calculated in relation to pH (defined by the best sensitiv-
ity on ROC cut-off for survival) and in-hospital mortality.
An additional outcome measure was direct monetary
costs associated with the use of rFVIIa for cases deemed
inappropriate.
Statistical analysis
The main variables present in this study were pH and
in-hospital mortality. Other covariates included per-
tained to the patient’s physiological state (ISS, AIS for
head injury, gender, age, base deficit, lactate, fibrinogen,
rate of RBC transfusion within 6h of hospitalization and
INR).
Last resort use of rFVIIa was defined based on ROC
analysis for survival as aforementioned. The ROC curve
was determined to define a specific pH cutoff at which
the test could appropriately discriminate the two groups
based on survival. From this value, the sensitivity, speci-
ficity, PPV and NPV were derived.
Potential determinants of rFVIIa failure were analyzed
through a subgroup analysis of baseline characteristics,
including degree of shock and acidosis, age, ISS, coagulo-
pathy, rFVIIa dose regimens, and rates of RBC transfusion.
Continuous variables were expressed in standard devia-
tions, medians, means, or interquartile ranges (IQR);
these were compared using T-test or Mann-Whitney U
test. Categorical variables were presented as percentages,
and compared using chi-square or Fisher’s exact test. All
analyses were performed using SAS 9.1 (SAS Institute
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Inc., Cary, NC). Two-sided p values were used and statis-
tical significance was set at p < 0.05.
Results
A total of 7,076 patients were seen by the Sunnybrook
trauma team during the 6-year study period. Within this
group, 328 (4.6%) patients were massively transfused. Of
these, 72 (22%) patients received rFVIIa. One patient
was excluded due to absent pH data. Upon further
investigation, it was noted that this subject had a low
numerical ISS score, blunt trauma with no head injury,
and received only one dose of 200 µg/kg of rFVIIa,
given after 6.9 h in the hospital. He remained stable
throughout his hospital stay. Therefore, our study
cohort consisted of 71 massively transfused patients
who received rFVIIa and had known pH values, meeting
our entry criteria. All 71 patients had complete data sets
for all variables studied.
The area under the ROC curve analysis for pH and sur-
vival was approximately 0.70 for the pH value 7.02, which
had the highest sensitivity to identify survivors. The sen-
sitivity of pH > 7.02 to identify survival was 100% and
specificity of pH ≤ 7.02 for in-hospital mortality was
100%. The PPV was 56.7% and the NPV was 100%. The
use of this best cut-off for pH based on the ROC curve
for our subgroup analysis is supported by previous
research suggesting that the efficacy of rFVIIa decreases
by 90% when the body pH decreases from 7.4 to 7.0 [17].
Therefore, we divided our cohort into 2 groups based on
admission pH (patients with pH ≤ 7.02 were analyzed in
the last resort group while patients with pH > 7.02 in the
non-last resort group). Clinical characteristics and demo-
graphics of the entire study cohort and subgroups based
on pH are summarized in Table 1. Overall, there were no
significant differences between the two subgroups with
respect to age, gender, type of injury, ISS, Head AIS, and
dose of rFVIIa given. Baseline coagulation profiles
showed significant differences in platelets (p < 0.01) and
INR (p = 0.03), except for fibrinogen (p = 0.07). Addi-
tionally, the rate of bleeding using transfusion as a surro-
gate marker was significantly higher in the severely
acidotic group (4 RBC units per hour ± 1.5 vs. 3 ± 1.7;
p=0.03).
A comparison of mortality between the two groups is
shown in Table 2. Of the 11 severely acidotic (pH ≤
7.02) patients in the last resort group, all (100%) died.
Of the 60 less acidotic (pH > 7.02) patients in the non-
last resort group, 26 (43%) died.
The vast majority, 72% of rFVIIa-treated patients
received only 1 dose, while 24% received 2 doses, and 4%
received 3 doses after being admitted to the hospital. The
first dose was administered after a median time interval
of 4.5h (2.7, 7.7). Repeated doses were administered after
an average time interval of 2.3h. This indicated that as
the patient’s condition deteriorated, more doses of rFVIIa
were administered in an expedited fashion. The median
initial dose was 85.7µg/kg (61.6, 102.8). This was also the
overall median dosage, as most patients only received 1
dose.
Of note, a transfusion medicine specialist at SHSC
approved the use of rFVIIa as a final alternative when all
potential interventions failed. In the years 2000 and 2001,
low doses of 17.1µg/kg of rFVIIa were administered after
patients received more than 20 units of RBCs. However,
following a supportive randomized control trial on rFVIIa
in trauma [8], fewer units of RBCs were noted to be
transfused prior to rFVIIa administration and more doses
of rFVIIa were given from 2002 onwards.
Table 1 Demographics & Baseline Characteristics
Variable Last resort (n=11) Non-last resort (n=60) P Value
Age (years) 27 (22, 39) 35 (24, 48) 0.14
Male (%) 82 63 0.3
Penetrating (%) 45 28 0.2
ISS 47 (±16) 43(±15) 0.4
Head AIS 0 (0, 2) 2 (0, 5) 0.1
Platelets 76 (±57) 184 (±95) <0.01
Fibrinogen 0.64 (±0.3) 0.9 (±0.5) 0.07
INR 2.1 (1.8,2.7) 1.4(1.2, 1.6) 0.03
Hemoglobin 83 (±17) 100 (±28) 0.02
pH 6.87 (±0.11) 7.26 (±0.11) <0.01
Rate of Bleeding (RBC/hr) 4 (±1.5) 3 (±1.7) 0.03
Time to rFVIIa (hr) 3.7 (±2.2) 6.2 (4.5) 0.04
rFVIIa Dose (ug/Kg) 89 (±43) 116 (±79) 0.14
> 1 rFVIIa doses (%) 9 33 0.05
Values are presented as mean (±SD) or median (IQR - Interquartile Range) when appropriate. ISS, injury severity score; AIS, abbreviated injury scale; INR,
international normalized ratio; RBC/hr, units of red blood cells per hour in the first 6 hrs of admission; Statistical significance was set at p<0.05
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The total cost of administrating sufficient doses of
rFVIIa to the 11 patients as a last resort was approxi-
mately $75,162 (CA). This monetary cost was measured
solely based on the amounts of doses of rFVIIa given
and excluded other expenditures associated with the
administration of the drug. In the United States of
America, a low dose (1,200 µg or 17.1µg/kg on a 70 kg
average adult) of rFVIIa is the smallest available unit
dose that costs approximately the same as 8 units of
plasma [23]. The price of one unit of plasma is approxi-
mately $120 (USD), including expenditures related to
administering them [23].
Discussion
Over the last decade, rFVIIa has been explored as a
potential treatment for many coagulopathic states other
than congenital conditions and hemophilias [7,11,24] .
Theoretically, rFVIIa seems to be an appealing option
following trauma because of its systemic intravenous
administration and swift mechanism of action, acting at
the injury site by binding to exposed tissue factor, and
expediting the generation of thrombin on activated pla-
telets to propel the coagulation cascade forward. How-
ever, in the context of massive hemorrhage, there are
potential limiting factors such as acidosis and refractory
shock.
From this study, a pH of 7.02 had the best sensitivity
on the ROC curve for discriminating survivors and non-
survivors. A pH > 7.02 was 100% sensitive at identifying
potential survivors, reassuring the clinician that no
probable survivors could have been missed if this pH
cut-off was adopted. Thus, a pH of 7.02 may be used as
a potential guideline or measure at which the adminis-
tration of rFVIIa should not be considered for patients
who are severely acidotic. The pH level of these patients
appeared to be a key determining factor in the success
of rFVIIa. As noted, there was a remarkable 100% mor-
tality noted in coagulopathic and severely acidotic
patients (pH ≤ 7.02) who had high bleeding rates,
despite the use of rFVIIa. This is corroborated by recent
research suggesting that the efficacy of rFVIIa decreases
by 90% when the body pH decreases from 7.4 to 7.0
[17]. However, in a recent animal model of lactic acido-
sis, the effectiveness of rFVIIa in correcting abnormal
INR values at a mean pH of 7.14 was unaffected [18].
This suggests that other factors may influence its effi-
cacy in clinical settings.
In keeping with our findings, data from the Australia
and New Zealand Haemostasis Registry on 10 years of
the use of rFVIIa in Australia and New Zealand which
reports on the outcomes of 2181 trauma cases, the single
most important predictor of the effect of rFVIIa on
bleeding and 28-day mortality was pH [25]. In their mul-
tivariate analysis, for every 0.1 decline in pH, there were
associated increases in non-responders to rFVIIa use and
mortality rates [25]. Their unadjusted analysis on the
relationship between 28-day mortality and pH showed
that patients with pH < 6.90 had a mortality rate of 98%
while the group with 7.30<pH<7.39 had a mortality of
23% [25]. Although the pH of 6.90 did not coincide with
our threshold of 7.02, the pattern is apparent that mortal-
ity percentage drastically increases with decreases in pH.
Logistic regression analysis was conducted and values for
the odds ratio were obtained for the effect on bleeding
and pH, as well as 28-day mortality and pH. For both, an
inverse correlation was seen, in that when pH decreased,
the odds ratio for mortality increased [25]. Furthermore,
outside of the trauma literature, a study by Karkouti et al.
found that the administration of rFVIIa should be expe-
dited in order to increase its efficacy in cardiac surgery
[24].
An additional factor that must be considered is the
impact of other variables, such as rate of bleeding and
baseline physiologic factors on rFVIIa, particularly tem-
perature. Hypothermia is a well-known complication
seen in the natural progression of traumatic injury,
blood loss, hypovolemia, and shock [26]. While our
study identifies correlations of pH with the effectiveness
of rFVIIa, a recently conducted study by Meng et al.,
suggests that a decrease in temperature from 37°C to
33°C also results in a reduction of rFVIIa’s activity by
20% [17]. The Australia and New Zealand Haemostasis
Registry also presented graphical data pertaining to the
effect of decreases in temperature and response of
bleeding to rFVIIa administration in trauma patients. In
fact, for ≤ 33.5°C, 70.7% of trauma patients had an
unchanged bleeding response; and for normal physiolo-
gic temperature range (36.6-37.5°C), 38% had an
unchanged bleeding response after receiving rFVIIa [25].
The registry also found that as pH is decreased, the
activity of rFVIIa is reduced [25]. Finally, a study by
Knudson et al analyzed subgroup of patients who
received rFVIIa and lived at least 24 hr versus those
who received rFVIIa and died. In this study, predictors
of death included a low pH, a low platelet count, a
more severe base deficit, and a higher transfusion rate
[27]. In our present study, higher transfusion rates were
also associated with failure of rFVIIa and increased
Table 2 pH & In-hospital Mortality















PPV, positive predictive value; NPV, negative predictive value
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mortality. These findings indicate that the efficacy of
rFVIIa in coagulopathic, acidotic patients with high
rates of bleeding is compromised with pH and tempera-
ture reductions.
As the patient’s condition deteriorates over time due
to failure of standard therapies, the pH drastically
decreases and the activity of rFVIIa is virtually nonexis-
tent, which makes it a challenge to consider the use of
rFVIIa as a last resort. Thus, current recommendations
on its use as an alternative to manage coagulopathy in
trauma when other interventions fail should be taken
with caution.
The high monetary cost of rFVIIa administration, with
no strong evidence of survival benefit [7,11] and
increased risks of thrombotic complications [12], also
calls for a review of guidelines recommending the use of
this medication for traumatic coagulopathy. The cost-
effectiveness of using rFVIIa as a last resort therapy for
critical bleeding requiring massive transfusion was
recently evaluated [19]. The incremental costs of rFVIIa
increased with severity of illness and transfusion
requirement, and were unacceptably high (> US$100,000
per life-year) for most patients [19]. Overall, thought
must be given to the expense of rFVIIa, and its utility as
a last resort.
Alternatively, a more affordable and effective manage-
ment strategy for traumatic coagulopathy is available. A
recently conducted large randomized control trial
(CRASH-2) involving 20,000 patients found that tranexa-
mic acid reduced the risk of death in hemorrhaging
trauma patients and should be recommended in bleeding
trauma situations [28]. International cost-analyses sup-
porting the use of tranexamic acid as opposed to admin-
istering rFVIIa found that the cost of giving tranexamic
acid compared to not giving it was $18,025 in Tanzania,
$20,760 in India and $48,002 in the UK [29]. The case
being made for increased administration of tranexamic
acid is bolstered by the lack of increased thromboembolic
events observed in the CRASH-2 trial. In Total Knee
Arthroplasty (TKA), a reduction in the number of blood
transfusions has also been observed with no increase in
symptomatic thromboembolic phenomena [30]. Tranexa-
mic acid may not only be helpful from a biological per-
spective, but also in a monetary manner, in reducing
resources in obtaining and providing blood products
[30,31].
Limitations
The main limitations of this study are its retrospective
nature, small size of the severely acidotic (pH ≤ 7.02)
subgroup, and the changes over time with respect to the
use of rFVIIa. Towards the start of the study period, this
drug was dosed as low as 17.1µg/kg, and was considered
as a final alternative therapy. However, further to
research advances at the time, a shift towards increased
doses and earlier use was noted by the year 2002, which
continued to evolve until the end of the study period.
This may also have had some impact upon observed
results. The pH data reflects the patient’s condition on
arrival, which might not represent changes in degrees of
acidosis immediately before the administration of the
drug. However, the drug was administered only 3.7h after
admission for the severely acidotic group and 6.2h for the
less acidotic patients when other standard therapies had
failed; thus a worsening pH level is intuitively expected in
these clinical situations. The area under the ROC curve
was tabulated to be 0.70, indicating potential for a more
accurate cutoff for determining at which pH range the
administration of rFVIIa should be more reserved.
Finally, we did not have information on all co-morbidities
that may have contributed to mortality.
Conclusions
Our study found no utility of rFVIIa in treating coagulo-
pathic trauma patients with pH ≤ 7.02 and high rates of
bleeding (4 units of RBC/h); and thus restrictions should
be set on its usage in these circumstances. Furthermore,
the lack of evidence demonstrating any survival benefit
of rFVIIa in trauma, in conjunction with the potential
increased risk of thromboembolic complications and
high monetary costs of its off-label use, renders its uti-
lity highly questionable in such situations.
Future research should be conducted in finding alter-
natives to rFVIIa in the management of trauma coagulo-
pathy. We hope our findings will guide physicians when
deciding on the inclusion of this drug as part of massive
transfusion protocols in trauma.
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